A Study of JMT203 in Patients With Cancer Cachexia

Required: GDF15 serum GDF-15 ≥1300 pg/ml (≥1300 pg/ml)

Serum Growth Differentiation Factor 15 （GDF-15） levels ≥1300 pg/ml within 28 days prior to the first study drug administration (applicable to the cohort expansion phase only)

Must have received: anti-tumor treatment — ongoing or completed

ongoing or completed anti-tumor treatment, and no significant tumor progression within 28 days prior to the first drug administration

Cannot have received: prescription medications for appetite enhancement or improve weight loss (anamorelin, medroxyprogesterone acetate, dronabinol, medical marijuana)

Patients who have taken any prescription medications for appetite enhancement or improve weight loss within 28 days or 5 half-lives (whichever is shorter) before the first study drug administration

Cannot have received: systemic glucocorticoids (prednisone)

Exception: excluding pretreatment for antitumor therapy

Initiation of systemic glucocorticoids (prednisone >10 mg/day or equivalent doses of other similar drugs) or other immunosuppressive therapies within 28 days before the first study drug administration, excluding pretreatment for antitumor therapy

Cannot have received: tube feeding or parenteral nutrition therapy

Patients receiving tube feeding or parenteral nutrition therapy during the screening period

Cannot have received: other clinical study medications

Patients who have received other clinical study medications within 4 weeks or 5 half-lives (whichever is shorter) before the first study drug administration